GLP-1 Brands

min read

Retatrutide and Autoimmune Disease: Safety, Evidence, and UK Guidance

Written by

Bolt Pharmacy

Published

18/8/2026

Last Updated

Retatrutide and autoimmune disease is an emerging area of clinical interest, as this investigational triple receptor agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously — shows considerable promise for obesity and type 2 diabetes management. For the many people living with autoimmune conditions such as rheumatoid arthritis, lupus, or inflammatory bowel disease, where obesity can worsen disease course, an effective metabolic therapy is particularly appealing. However, retatrutide remains unlicensed in the UK, its safety in autoimmune populations is unestablished, and important questions around drug interactions and immune modulation require careful consideration.

Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) not yet licensed in the UK, with no established safety data in people with autoimmune conditions.

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from licensed agents such as semaglutide and tirzepatide.
As of mid-2025, retatrutide holds no MHRA or EMA marketing authorisation and cannot be legally prescribed in the UK outside a regulated clinical trial.
Preliminary evidence suggests GLP-1 receptor agonism may have anti-inflammatory properties, but no robust clinical trial data confirm immunological benefits of retatrutide specifically.
People with autoimmune conditions taking immunosuppressants, biologics, or corticosteroids face unstudied interaction risks and altered gastrointestinal tolerability.
Common side effects mirror other GLP-1-based therapies: nausea, vomiting, diarrhoea, and potential pancreatitis or gallbladder disease requiring prompt medical assessment.
Suspected adverse reactions should be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What Is Retatrutide and How Does It Work?
Using Retatrutide If You Have an Autoimmune Condition
Potential Risks and Safety Considerations
Current MHRA and NICE Guidance on Retatrutide
Talking to Your GP or Specialist Before Starting Treatment
Scientific References
Frequently Asked Questions

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist activating GLP-1, GIP, and glucagon receptors, currently unlicensed by the MHRA or EMA and available only within Phase 3 clinical trials.

Retatrutide is an investigational medication under clinical development for the treatment of obesity and type 2 diabetes. It belongs to a novel class of drugs known as triple receptor agonists, meaning it simultaneously activates three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism of action distinguishes retatrutide from existing approved agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist).

By activating the GLP-1 receptor, retatrutide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, and reduces appetite by acting on satiety centres in the brain.^[6] The GIP receptor component further supports insulin release and may contribute to improved fat metabolism. The addition of glucagon receptor agonism is thought to promote energy expenditure and may support hepatic fat reduction, though the human evidence for these glucagon-mediated benefits remains early and limited to preclinical and Phase 2 data.^[7]^[1]

A Phase 2 randomised controlled trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023) demonstrated substantial weight reduction — in some participants exceeding 24% of body weight over 48 weeks — alongside improvements in glycaemic control and cardiometabolic markers. These results have generated considerable scientific interest. Long-term safety, cardiovascular outcomes, and optimal dosing are currently under investigation in ongoing Phase 3 programmes (registered on ClinicalTrials.gov and the EU Clinical Trials Register).

As of mid-2025, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains unavailable as a licensed treatment in the United Kingdom.^[8] This regulatory status is subject to change as Phase 3 data mature and regulatory submissions are made.

Using Retatrutide If You Have an Autoimmune Condition

No robust clinical trial data confirm that retatrutide is safe or beneficial in people with established autoimmune conditions, and potential interactions with immunosuppressive therapies remain unstudied.

For individuals living with autoimmune conditions — such as rheumatoid arthritis, systemic lupus erythematosus (SLE), inflammatory bowel disease, multiple sclerosis, or type 1 diabetes — the prospect of a highly effective weight-loss and metabolic therapy is understandably appealing. Obesity is known to worsen inflammation and can exacerbate the course of many autoimmune diseases, so effective weight management carries genuine clinical relevance in this population.

There is emerging preclinical and early clinical evidence suggesting that GLP-1 receptor agonism may have anti-inflammatory properties. Some research indicates that GLP-1 signalling can modulate immune cell activity and reduce pro-inflammatory cytokine production, and systematic reviews of GLP-1 receptor agonists in metabolic disease have noted reductions in inflammatory markers such as C-reactive protein.^[9]^[10] These findings have prompted interest in whether drugs like retatrutide might offer immunomodulatory benefits alongside their metabolic effects. However, it is important to note that these findings are preliminary, and no robust clinical trial data currently exist to confirm meaningful immunological benefits of retatrutide specifically in people with established autoimmune conditions. Retatrutide is investigational and is not established as a treatment for any autoimmune disease, including type 1 diabetes.

Equally, there is a theoretical concern that altering metabolic and immune signalling pathways simultaneously could have unpredictable effects in individuals whose immune systems are already dysregulated or who are taking immunosuppressive therapies. People with autoimmune conditions are frequently prescribed disease-modifying antirheumatic drugs (DMARDs), biologics, or corticosteroids. The potential for pharmacological interactions with retatrutide has not been adequately studied, and the effects of these medicines on gastrointestinal function may influence tolerability of GLP-1-based therapies. Until dedicated clinical trials include sufficient numbers of participants with autoimmune diagnoses, clinicians and patients should approach this combination with appropriate caution and careful multidisciplinary clinical oversight.

Consideration	Detail	Risk Level	Advice
Immunosuppressant / biologic interactions	Pharmacological interactions with DMARDs, biologics, and corticosteroids have not been adequately studied	Unknown	Discuss all current immunosuppressive therapies with your specialist before considering retatrutide
Autoimmune flare risk	No established evidence retatrutide triggers flares; however, immune-adjacent pathway modulation cannot be excluded	Uncertain	Report any new joint pain, rash, fatigue, or GI disturbance to a clinician promptly
GI tolerability in autoimmune disease	Immunosuppressive medicines may alter GI function, affecting tolerability and oral drug absorption during dose escalation	Moderate	Monitor concomitant oral medicine efficacy; seek multidisciplinary oversight
Corticosteroid use	Corticosteroids promote weight gain and insulin resistance, potentially influencing response to retatrutide	Low–Moderate	Inform prescriber of steroid use; monitor glycaemic and weight outcomes closely
Potential anti-inflammatory benefit	Preclinical and early clinical data suggest GLP-1 agonism may reduce pro-inflammatory cytokines and CRP; retatrutide-specific data lacking	Preliminary only	Do not use retatrutide as a treatment for autoimmune disease; evidence is insufficient
Pancreatitis risk	GLP-1-based therapies are associated with acute pancreatitis; relevant in autoimmune conditions affecting the pancreas (e.g., type 1 diabetes)	High if history present	Avoid if history of pancreatitis; seek immediate assessment for severe persistent abdominal pain
Regulatory and access status (UK)	Retatrutide holds no MHRA marketing authorisation or NICE recommendation as of mid-2025; no EAMS route established	N/A	Access only via regulated clinical trial; report suspected adverse reactions via MHRA Yellow Card scheme

Potential Risks and Safety Considerations

Retatrutide shares GLP-1 class risks including pancreatitis, gallbladder disease, and dehydration-related AKI; in autoimmune patients, altered gastrointestinal function and immunosuppressive drug interactions add further complexity.

Based on data from Phase 2 clinical trials, retatrutide shares a broadly similar adverse effect profile to other GLP-1-based therapies, though the addition of glucagon receptor agonism introduces some distinct considerations. The most commonly reported side effects include:

Gastrointestinal symptoms: nausea, vomiting, diarrhoea, and constipation — particularly during dose escalation
Decreased appetite and early satiety
Injection site reactions (retatrutide is administered as a subcutaneous injection)
Mild increases in heart rate, a known class effect of GLP-1 receptor agonists^[20]^[17]
Potential risk of hypoglycaemia, particularly when used alongside insulin or sulphonylureas

The following additional class-effect safety considerations apply to GLP-1 receptor agonist-based therapies and are relevant to retatrutide, based on the established safety profiles of licensed comparators (see EMC SmPCs for semaglutide/Wegovy® and liraglutide/Saxenda®):

Pancreatitis: Severe, persistent abdominal pain — particularly pain radiating to the back — may indicate acute pancreatitis and requires immediate medical assessment. GLP-1 receptor agonists have been associated with pancreatitis; treatment should be discontinued if this is suspected.^[12]^[17]
Gallbladder disease: Rapid weight loss and GLP-1 receptor agonism are associated with an increased risk of cholelithiasis (gallstones) and cholecystitis.^[13]^[14] Symptoms such as upper abdominal pain, particularly after eating, should be evaluated promptly.
Dehydration and acute kidney injury (AKI): Vomiting and diarrhoea can lead to dehydration, which may precipitate AKI, particularly in those taking medicines that affect renal function (such as NSAIDs or diuretics). Maintaining adequate fluid intake is important.
Diabetic retinopathy: Rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy in some patients.^[17]^[18] Those with pre-existing retinopathy should be monitored appropriately.
Pregnancy and breastfeeding: GLP-1 receptor agonists are not recommended during pregnancy or breastfeeding. Women of childbearing potential should discuss contraception and the need for a washout period before conception with their clinician, as advised in the SmPCs of licensed comparators.

For individuals with autoimmune conditions, additional considerations apply. Those taking immunosuppressive medications may have altered gastrointestinal function, which could affect tolerability of retatrutide or the absorption of concomitant oral medicines. Corticosteroid use, common in autoimmune disease management, can promote weight gain and insulin resistance — factors that may influence both the need for and response to retatrutide.

There is currently no established evidence that retatrutide triggers autoimmune flares or worsens existing autoimmune conditions. However, because the drug modulates immune-adjacent pathways and has not been studied in this population specifically, the possibility cannot be excluded. Individuals with a history of pancreatitis or pre-existing thyroid disease should discuss this with their clinician before considering any GLP-1-based therapy; any new neck lump, difficulty swallowing, hoarseness, or breathlessness should be reported to a healthcare professional promptly. Any new or worsening symptoms — including joint pain, rash, fatigue, or gastrointestinal disturbance — should also be reported without delay.

Reporting side effects: If you experience a suspected adverse reaction to any medicine, including within a clinical trial, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Current MHRA and NICE Guidance on Retatrutide

Retatrutide has no MHRA marketing authorisation or NICE recommendation as of mid-2025; the only legitimate UK access route is participation in a regulated clinical trial.

As of mid-2025, retatrutide has not been granted a marketing authorisation by the MHRA in the United Kingdom, nor has it been assessed or recommended by the National Institute for Health and Care Excellence (NICE).^[8] It therefore cannot be legally prescribed or dispensed as a licensed medicine within the NHS or private healthcare settings in the UK. Patients should be aware that any product being sold or offered as retatrutide outside of a regulated clinical trial setting is unlicensed and potentially unsafe.

In principle, pre-licence access routes such as the MHRA's Early Access to Medicines Scheme (EAMS) or named-patient unlicensed supply can exist for investigational medicines in exceptional circumstances; however, as of mid-2025, no such route has been established for retatrutide.^[25]^[26] Participation in a regulated clinical trial therefore remains the only practical legitimate route to accessing this medication in the UK, and doing so ensures appropriate medical supervision and monitoring.

NICE guidance on the management of obesity supports the use of licensed GLP-1 receptor agonists within defined eligibility criteria and specialist weight management services. Specifically:

Semaglutide (Wegovy®) is recommended by NICE (Technology Appraisal TA875) for adults with a BMI of 35 kg/m² or above (or 30–34.9 kg/m² in certain higher-risk groups) alongside at least one weight-related comorbidity, when used within a specialist weight management service. Use is time-limited (up to two years in the first instance).
Liraglutide (Saxenda®) is recommended by NICE (Technology Appraisal TA664) for adults with a BMI of 35 kg/m² or above (or lower in certain groups) with prediabetes and cardiovascular risk factors, again within a specialist tier 3 weight management service.

These recommendations are subject to ongoing review as new evidence emerges. Retatrutide would need to complete Phase 3 clinical trials, demonstrate a favourable benefit-risk profile, and undergo full regulatory review before it could be considered for NICE appraisal.

The EMA similarly has not approved retatrutide, though regulatory submissions may follow the completion of ongoing Phase 3 trials. Patients interested in accessing retatrutide may wish to enquire about eligibility for clinical trials through their specialist or via the NIHR Be Part of Research portal (www.nihr.ac.uk/patients-and-public/be-part-of-research).

Talking to Your GP or Specialist Before Starting Treatment

Anyone with an autoimmune condition interested in retatrutide should consult their GP or specialist before taking any steps, and must not attempt to obtain it from unregulated online sources.

If you have an autoimmune condition and are interested in retatrutide — whether for weight management, glycaemic control, or its potential anti-inflammatory properties — it is essential to have an open and informed conversation with your GP or relevant specialist before taking any steps. This is particularly important given that retatrutide is not yet licensed in the UK and that its safety profile in people with autoimmune diseases has not been formally established.

Do not attempt to obtain retatrutide from online vendors or unregulated sources. Products sold outside of regulated clinical trials are unlicensed, may be counterfeit or unsafe, and are not subject to any medical oversight.

When speaking with your healthcare team, consider raising the following points:

Your current medications: Discuss any immunosuppressants, biologics, corticosteroids, or other treatments you are taking, and ask whether there are known or theoretical interactions with GLP-1-based therapies.
Your autoimmune disease activity: If your condition is currently flaring or poorly controlled, this may not be an appropriate time to introduce a new investigational agent.
Your weight and metabolic health goals: Your GP or specialist can help determine whether existing licensed treatments — such as semaglutide (Wegovy®, recommended by NICE TA875 within specialist weight management services) — might be appropriate and accessible for you now. Tirzepatide is currently licensed in the UK for type 2 diabetes management; its availability for weight management is subject to current MHRA licensing and NICE appraisal decisions, which your clinician can advise on.^[28]^[29]
Clinical trial eligibility: Ask whether you might be suitable for a registered clinical trial involving retatrutide or similar agents via the NIHR Be Part of Research portal.
Pregnancy and reproductive planning: If you are pregnant, breastfeeding, or planning a pregnancy, discuss this with your clinician before starting any weight-management therapy, as GLP-1-based medicines are not recommended in these circumstances.

Seek urgent medical attention if you experience severe abdominal pain (particularly pain radiating to the back), signs of a serious allergic reaction (such as swelling of the face, lips, or throat, or difficulty breathing), or persistent vomiting leading to inability to keep fluids down. These symptoms require same-day or emergency assessment.

You should also seek prompt medical advice if you experience any unexplained new symptoms after starting any weight-management therapy, including signs of an autoimmune flare, new gastrointestinal disturbance, or any other concerning change in your health. Your GP can refer you to a specialist obesity service or a relevant autoimmune disease clinic if more complex management is needed.

If you experience a suspected side effect from any medicine, report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Staying informed and working collaboratively with your healthcare team remains the safest approach when navigating emerging treatments.

Scientific References

Frequently Asked Questions

Is retatrutide safe to use if you have an autoimmune condition?

There is currently no established clinical trial evidence confirming that retatrutide is safe in people with autoimmune conditions. Until dedicated studies are completed, individuals with autoimmune diseases should only consider retatrutide under close specialist supervision within a regulated clinical trial.

Can retatrutide be prescribed in the UK for weight loss?

No. As of mid-2025, retatrutide has not received a marketing authorisation from the MHRA and cannot be legally prescribed in the UK. The only legitimate route to access it is through participation in a regulated clinical trial.

Could retatrutide trigger or worsen an autoimmune flare?

There is currently no established evidence that retatrutide triggers or worsens autoimmune conditions, but because it modulates immune-adjacent pathways and has not been studied in this population, the possibility cannot be excluded. Any new or worsening symptoms should be reported to a healthcare professional promptly.

Disclaimer & Editorial Standards

The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.

The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.

Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.

Book a discovery call

and discuss your eligibility for the Fella Program

Book your free call